FDA Heralds The End Of Switching Studies For Biosimilar Interchangeability
Guidance Suggests Analytical And Clinical Data Can Be Sufficient To Support Application
New guidance published by the US FDA suggests that switching studies will no longer be expected as standard to support determinations of biosimilar interchangeability, with the agency instead suggesting that analytical and clinical data will suffice.
